查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1880600

人類纖維蛋白原濃縮物市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察與預測（2024-2032 年）

Human Fibrinogen Concentrates Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 125 Pages | 商品交期: 請詢問到貨日

價格

人類纖維蛋白原濃縮物市場成長驅動因子

由於外科手術的增加、人們對先進止血療法的認識不斷提高以及血漿衍生技術的持續進步，全球人類纖維蛋白原濃縮物市場正在快速擴張。根據最新估計，2024 年全球市場規模約為 7.687 億美元，預計到 2025 年將達到 8.534 億美元。預計到 2032 年，市場規模將加速成長至 19.011 億美元，預測期內複合年增長率 (CAGR) 為 12.1%。歐洲在全球市場佔主導地位，2024 年市佔率達到 48.39%，這得益於其強大的生產能力、監管審批以及外科手術和出血性疾病的高發生率。

人類纖維蛋白原濃縮物是一種重要的血漿衍生止血產品，用於快速恢復因創傷、手術或先天性纖維蛋白原缺乏症（例如無纖維蛋白原血症）而導致嚴重出血患者的纖維蛋白原水平。全球手術負擔的不斷加重仍然是推動市場需求的主要因素。例如，全印度醫學科學研究所 (AIIMS) 報告稱，2022 年 9 月印度進行了超過 25 萬例全膝關節置換手術，顯示市場對可靠的止血解決方案的需求日益增長。 LFB、CSL、Octapharma AG 和 Grifols S.A. 等領先企業持續投資於研發、產品線拓展和臨床試驗，以鞏固其全球影響力。 2024 年 2 月，Grifols 公佈了 Biotest 的纖維蛋白原濃縮物 BT524 的 III 期臨床試驗的積極結果，證明其在治療獲得性纖維蛋白原缺乏症 (AFD) 方面的療效。

市場推動因素

主要推動因素之一是全球外科手術數量的快速增長，這歸因於人口老化、慢性病增多、不健康的生活方式以及創傷病例的增加。隨著外科手術變得越來越複雜，對快速有效的術中止血液的需求也相應增長。根據美國國立衛生研究院 (NIH) 發布的 "2024 年全球心臟外科手術量報告" ，高收入國家平均每年每 10 萬人進行 123.2 例心臟手術。減少術中和術後併發症的需求日益增長，顯著加速了纖維蛋白原濃縮物相對於新鮮冷凍血漿 (FFP) 和冰凍血漿等傳統選擇的應用。

市場限制因子

然而，人類纖維蛋白原濃縮物的高成本仍然是一個主要阻礙因素，尤其是在新興經濟體。複雜的生產流程、對捐獻血漿的需求以及嚴格的監管規程都顯著增加了生產成本。例如，1克FIBRINOREL的商業價格約為185.4美元，限制了其在低收入地區的普及。有限的保險覆蓋範圍進一步阻礙了其在發展中國家的應用，並減緩了其市場滲透速度。

市場機會

全球和區域製造商之間不斷擴大的策略聯盟正在創造強勁的成長機會。製藥公司、生技公司和血漿分離專家之間的合作能夠加快產品開發速度並深化市場滲透。 2024年6月，Plasmagen Biosciences與CSL Behring合作，開始在印度生產和銷售Hemocomplettan P，這標誌著在改善發展中國家市場可及性方面邁出了重要一步。除了不斷擴大的研發管線外，政府為改善外科基礎設施所做的努力預計也將支持長期成長。

市場挑戰

供應鏈的複雜性仍然是一項重大挑戰。人類纖維蛋白原濃縮物需要強大的供體網絡、嚴格的冷鏈物流、高技能人員以及嚴格的批次放行監管。這些因素為新生產商設置了很高的進入門檻，減緩了競爭擴張速度，並限制了全球供應。

產業趨勢

一個關鍵的新興趨勢是轉向研發管線創新，以縮短給藥時間、實現劑量標準化並改善臨床療效。傳統的冷凍纖維蛋白原補充劑受限於劑量差異和耗時的解凍過程。像 Grifols 的 BT524 這樣的新產品，預計將於 2025 年在 III 期臨床試驗中達到其主要目標，在治療獲得性纖維蛋白原缺乏症 (AFD) 方面具有更可預測的療效和更快速的給藥方式。這些進步有望重新定義全球臨床實踐。

市場區隔概覽

依應用領域

預計到2024年，獲得性纖維蛋白原缺乏症和外科手術領域將成為市場主導，這主要得益於創傷病例的增加以及全球外科手術數量的增長。作為參考，2020-2021年澳洲共進行了12,700例冠狀動脈繞道手術（CABG）。先天性纖維蛋白原缺乏症仍是第二大區隔市場，這主要歸功於其較高的盛行率（每百萬人口1-30例）以及人們對該疾病的認識和診斷率的不斷提高。

依最終使用者

預計到2024年，醫院領域將佔最大市場佔有率，這得益於其先進的基礎設施和龐大的手術量。根據世界衛生組織統計，全球每年進行的外科手術數量超過3億例，增加了醫院對纖維蛋白原濃縮物的依賴。

區域洞察

歐洲

歐洲將佔最大的區域市場佔有率，到2024年市場規模將達到3.72億美元，這得益於該地區強大的行業地位以及對諸如Octapharma的Fibriga等產品的早期應用。

北美

成長的推動因素是出血性疾病發生率的上升（據估計，美國約有33,000人患有血友病）以及健全的醫療保健生態系統。

亞太地區

亞太地區未來成長潛力巨大，這得益於人口老化、慢性病增多以及基礎設施建設，例如旨在升級100家醫院的 "2024 100-4-100" 計畫。

拉丁美洲、中東和非洲

儘管這些地區的市場佔有率較小，但它們正受益於人們意識的提高和醫療保健投資的增加。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場推動因素
  • 市場阻礙因素
  • 市場機遇
  • 市場挑戰
  • 市場趨勢

第四章：關鍵洞察

  • 人類纖維蛋白原產業的技術現況與趨勢
  • 產業進入障礙（財務、技術、人才、品牌）
  • 消費者偏好分析
  • 區域環境對人類纖維蛋白原產業的影響
  • 通貨膨脹對人類纖維蛋白原產業的影響
  • 人工智慧的變革力量人工纖維蛋白原產業
  • 全球互惠關稅對產業的影響
  • 行業政策與法規
  • 人類纖維蛋白原濃縮物市場的上下游分析

第五章：全球人類纖維蛋白原濃縮物市場分析、洞察與預測（2019-2032）

  • 市場分析、洞察與預測 - 依應用領域劃分
    • 先天性纖維蛋白原缺乏症
    • 後天性纖維蛋白原缺乏症和手術
    • 其他
  • 市場分析、洞察與預測 - 依最終用戶劃分
    • 醫院
    • 專科診所
    • 其他
  • 市場分析、洞察與預測 - 依地區劃分
    • 北美美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美人類纖維蛋白原濃縮物市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲人纖維蛋白原濃縮物市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章：亞太地區人類纖維蛋白原濃縮物市場分析、洞察與預測（2019-2032）纖維蛋白原濃縮物市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲人類纖維蛋白原濃縮物市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第十章 中東與非洲人纖維蛋白原濃縮物市場分析、洞察與預測（2019-2032）

  • 依國家/地區
    • 海灣合作委員會 (GCC)
    • 南非
    • 其他中東和非洲國家/地區

第十一章：競爭分析

  • 全球市佔率分析 (2024)
  • 公司簡介
  • CSL
  • 格里福爾斯公司 (Grifols, S.A.)
  • LFB
  • 瑞信生命科學公司 (Reliance Life Sciences)
  • 上海瑞思血液製品有限公司 (Shanghai RAAS Blood Products Co., Ltd.)
  • 華潤博亞生物製藥集團股份有限公司 (China Resources Boya Biopharmaceutical Group Co., Ltd.)
  • 奧克塔製藥公司 (Octapharma AG)
Product Code: FBI113876

Growth Factors of human fibrinogen concentrates Market

The global human fibrinogen concentrates market is expanding rapidly as surgical volumes rise, awareness of advanced hemostatic therapies grows, and plasma-derived technologies continue to evolve. According to the latest estimates, the global market size stood at USD 768.7 million in 2024, is projected to reach USD 853.4 million in 2025, and is expected to accelerate to USD 1,901.1 million by 2032, growing at a strong CAGR of 12.1% during the forecast period. Europe dominated the global market with a 48.39% share in 2024, supported by strong manufacturing capabilities, regulatory approvals, and a high prevalence of surgical and bleeding-related disorders.

Human fibrinogen concentrates are essential plasma-derived hemostatic products used to rapidly restore fibrinogen levels in patients suffering from significant bleeding due to trauma, surgical procedures, or congenital deficiencies such as afibrinogenemia. Rising surgical burden worldwide continues to be a major demand driver. For example, the All India Institute of Medical Sciences (AIIMS) reported in September 2022 that over 250,000 total knee replacement surgeries were performed in India, highlighting the growing need for reliable hemostatic solutions. Key industry players-including LFB, CSL, Octapharma AG, and Grifols S.A.-continue to invest in R&D, portfolio expansion, and clinical trials to strengthen their global footing. In February 2024, Grifols reported positive Phase 3 results for Biotest's BT524, a fibrinogen concentrate demonstrating effectiveness in treating acquired fibrinogen deficiency (AFD).

Market Drivers

One of the leading drivers is the surging number of surgical procedures worldwide, driven by an aging population, rising prevalence of chronic diseases, unhealthy lifestyles, and increased trauma cases. As surgical complexity rises, demand for rapid, efficient intraoperative bleeding control increases proportionately. According to NIH's 2024 report on global cardiac surgical volume, high-income countries performed an average of 123.2 cardiac surgeries per 100,000 population annually. The growing need for reduced intraoperative and postoperative complications has strongly accelerated adoption of fibrinogen concentrates over traditional options such as fresh frozen plasma (FFP) and cryoprecipitate.

Market Restraints

However, the high cost associated with human fibrinogen concentrates remains a major limiting factor, particularly in emerging economies. Complex manufacturing processes, donor plasma requirements, and stringent regulatory protocols significantly elevate production costs. For example, the commercial price for FIBRINOREL 1g is approximately USD 185.4, restricting affordability in low-income regions. Limited reimbursement coverage further impedes adoption, slowing market penetration across developing countries.

Market Opportunities

Growing strategic collaborations among global and regional manufacturers are creating strong expansion opportunities. Partnerships between pharmaceutical companies, biotech firms, and plasma fractionation specialists enable faster product development and deeper market penetration. In June 2024, Plasmagen Biosciences partnered with CSL Behring to manufacture and commercialize Haemocomplettan P in India, marking a significant milestone for improving access in developing markets. Expanding R&D pipelines, along with government focus on improving surgical infrastructure, are expected to support long-term growth.

Market Challenges

Supply chain complexities remain a major challenge. Human fibrinogen concentrates require robust donor networks, stringent cold chain logistics, highly skilled personnel, and rigorous regulatory compliance for batch release. These factors create a high entry barrier for new manufacturers, slowing competitive expansion and limiting global supply.

Industry Trends

A key emerging trend is the shift toward pipeline innovations that offer faster administration, standardized dosing, and improved clinical outcomes. Cryoprecipitate-traditionally used for fibrinogen replenishment-faces limitations due to variable dosing and time-consuming thawing requirements. New products like Grifols' BT524, which met primary goals in a 2025 Phase 3 trial, offer more predictable efficacy and rapid administration for managing acquired fibrinogen deficiency (AFD). These advancements are expected to redefine global clinical practice.

Segmentation Overview

By Application

The acquired fibrinogen deficiency & surgical procedures segment dominated in 2024 due to rising trauma cases and increasing surgical volumes globally. For reference, Australia reported 12,700 coronary artery bypass graft (CABG) surgeries in 2020-2021. Congenital fibrinogen deficiency remains the second-largest segment, driven by its prevalence (1-30 cases per 1 million population) and increased awareness and diagnosis.

By End-user

The hospital segment accounted for the largest share in 2024, supported by advanced infrastructure and high surgical caseloads. According to WHO, global surgical volumes exceeded 300 million annually, reinforcing hospital dependency on fibrinogen concentrates.

Regional Insights

Europe

Europe held the largest regional share in 2024 with a market size of USD 372.0 million, supported by strong industry presence and early adoption of products like Octapharma's Fibryga.

North America

Growth is driven by rising bleeding disorder cases-approximately 33,000 U.S. males are estimated to have hemophilia-and a robust healthcare ecosystem.

Asia Pacific

APAC shows strong future growth potential due to aging populations, rising chronic conditions, and infrastructure initiatives like the 2024 100-4-100 Project, aimed at upgrading 100 hospitals.

Latin America & Middle East/Africa

These regions maintain smaller shares but are benefiting from rising awareness initiatives and healthcare investment.

Conclusion

With the global human fibrinogen concentrates market expected to reach USD 1,901.1 million by 2032, sustained growth will be driven by expanding surgical needs, strategic collaborations, and advancements in plasma-derived product innovation. The industry's future hinges on improved accessibility, cost optimization, and continued R&D progress.

Segmentation By Application

  • Congenital Fibrinogen Deficiency
  • Acquired Fibrinogen Deficiency & Surgical Procedures
  • Others

By End-user

  • Hospitals
  • Specialty Clinics
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Market Scope
  • 1.2. Market Segmentation
  • 1.3. Market Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Challenges
  • 3.5. Market Trends

4. Key Insights

  • 4.1. Human Fibrinogen Industry Technology Status and Trends
  • 4.2. Industry Entry Barriers (Financial, Technical, Talent, Brand)
  • 4.3. Consumer Preference Analysis
  • 4.4. The Impact of Regional Situation on Human Fibrinogen Industries
  • 4.5. The Impact of Inflation on Human Fibrinogen Industries
  • 4.6. The Transformative Power of AI on Human Fibrinogen Industries
  • 4.7. The Impact of Global Reciprocal Tariffs on the Industry
  • 4.8. Industry Policies and Regulation
  • 4.9. Human Fibrinogen Concentrates Market Upstream and Downstream Analysis

5. Global Human Fibrinogen Concentrates Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Application
    • 5.1.1. Congenital Fibrinogen Deficiency
    • 5.1.2. Acquired Fibrinogen Deficiency & Surgical Procedures
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By End-user
    • 5.2.1. Hospitals
    • 5.2.2. Specialty Clinics
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Latin America
    • 5.3.5. Middle East & Africa

6. North America Human Fibrinogen Concentrates Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Application
    • 6.1.1. Congenital Fibrinogen Deficiency
    • 6.1.2. Acquired Fibrinogen Deficiency & Surgical Procedures
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By End-user
    • 6.2.1. Hospitals
    • 6.2.2. Specialty Clinics
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Human Fibrinogen Concentrates Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Application
    • 7.1.1. Congenital Fibrinogen Deficiency
    • 7.1.2. Acquired Fibrinogen Deficiency & Surgical Procedures
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By End-user
    • 7.2.1. Hospitals
    • 7.2.2. Specialty Clinics
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 7.3.1. U.K.
    • 7.3.2. Germany
    • 7.3.3. France
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Scandinavia
    • 7.3.7. Rest of Europe

8. Asia Pacific Human Fibrinogen Concentrates Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Application
    • 8.1.1. Congenital Fibrinogen Deficiency
    • 8.1.2. Acquired Fibrinogen Deficiency & Surgical Procedures
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By End-user
    • 8.2.1. Hospitals
    • 8.2.2. Specialty Clinics
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. India
    • 8.3.4. Southeast Asia
    • 8.3.5. Rest of Asia Pacific

9. Latin America Human Fibrinogen Concentrates Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Application
    • 9.1.1. Congenital Fibrinogen Deficiency
    • 9.1.2. Acquired Fibrinogen Deficiency & Surgical Procedures
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By End-user
    • 9.2.1. Hospitals
    • 9.2.2. Specialty Clinics
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 9.3.1. Brazil
    • 9.3.2. Mexico
    • 9.3.3. Rest of Latin America

10. Middle East & Africa Human Fibrinogen Concentrates Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Application
    • 10.1.1. Congenital Fibrinogen Deficiency
    • 10.1.2. Acquired Fibrinogen Deficiency & Surgical Procedures
    • 10.1.3. Others
  • 10.2. Market Analysis, Insights and Forecast - By End-user
    • 10.2.1. Hospitals
    • 10.2.2. Specialty Clinics
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 10.3.1. GCC
    • 10.3.2. South Africa
    • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
    • 11.2.1. CSL
    • 11.2.2. Grifols, S.A.
    • 11.2.3. LFB
    • 11.2.4. Reliance Life Sciences
    • 11.2.5. Shanghai RAAS Blood Products Co., Ltd.
    • 11.2.6. China Resources Boya Biopharmaceutical Group Co., Ltd.
    • 11.2.7. Octapharma AG

List of Tables

  • Table 01: Global Human Fibrinogen Concentrates Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 02: Global Human Fibrinogen Concentrates Market Revenue (USD million) Forecast, By End-user, 2019-2032
  • Table 03: Global Human Fibrinogen Concentrates Market Revenue (USD million) Forecast, by Region, 2019-2032
  • Table 04: North America Human Fibrinogen Concentrates Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 05: North America Human Fibrinogen Concentrates Market Revenue (USD million) Forecast, By End-user, 2019-2032
  • Table 06: North America Human Fibrinogen Concentrates Market Revenue (USD million) Forecast, by Region, 2019-2032
  • Table 07: Europe Human Fibrinogen Concentrates Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 08: Europe Human Fibrinogen Concentrates Market Revenue (USD million) Forecast, By End-user, 2019-2032
  • Table 09: Europe Human Fibrinogen Concentrates Market Revenue (USD million) Forecast, by Region, 2019-2032
  • Table 10: Asia Pacific Human Fibrinogen Concentrates Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 11: Asia Pacific Human Fibrinogen Concentrates Market Revenue (USD million) Forecast, By End-user, 2019-2032
  • Table 12: Asia Pacific Human Fibrinogen Concentrates Market Revenue (USD million) Forecast, by Region, 2019-2032
  • Table 13: Latin America Human Fibrinogen Concentrates Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 14: Latin America Human Fibrinogen Concentrates Market Revenue (USD million) Forecast, By End-user, 2019-2032
  • Table 15: Latin America Human Fibrinogen Concentrates Market Revenue (USD million) Forecast, by Region, 2019-2032
  • Table 16: Middle East & Africa Human Fibrinogen Concentrates Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 17: Middle East & Africa Human Fibrinogen Concentrates Market Revenue (USD million) Forecast, By End-user, 2019-2032
  • Table 18: Middle East & Africa Human Fibrinogen Concentrates Market Revenue (USD million) Forecast, by Region, 2019-2032

List of Figures

  • Figure 01: Global Human Fibrinogen Concentrates Market Revenue Breakdown (USD million, %), By Region, 2024 & 2032
  • Figure 02: Global Human Fibrinogen Concentrates Market Value Share (%), By Application, 2024 & 2032
  • Figure 03: Global Human Fibrinogen Concentrates Market Value Share (%), By End-user, 2024 & 2032
  • Figure 04: Global Human Fibrinogen Concentrates Market Value Share (%), By Region, 2024 & 2032
  • Figure 05: North America Human Fibrinogen Concentrates Market Value (USD billion), by Application, 2024 & 2032
  • Figure 06: North America Human Fibrinogen Concentrates Market Value Share (%), by Application, 2024
  • Figure 07: North America Human Fibrinogen Concentrates Market Value (USD billion), by End-user, 2024 & 2032
  • Figure 08: North America Human Fibrinogen Concentrates Market Value Share (%), by End-user, 2024
  • Figure 09: North America Human Fibrinogen Concentrates Market Value (USD billion), By Country, 2024 & 2032
  • Figure 10: North America Human Fibrinogen Concentrates Market Value Share (%), By Country, 2024
  • Figure 11: Europe Human Fibrinogen Concentrates Market Value (USD billion), by Application, 2024 & 2032
  • Figure 12: Europe Human Fibrinogen Concentrates Market Value Share (%), by Application, 2024
  • Figure 13: Europe Human Fibrinogen Concentrates Market Value (USD billion), by End-user, 2024 & 2032
  • Figure 14: Europe Human Fibrinogen Concentrates Market Value Share (%), by End-user, 2024
  • Figure 15: Europe Human Fibrinogen Concentrates Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
  • Figure 16: Europe Human Fibrinogen Concentrates Market Value Share (%), By Country/Sub-Region, 2024
  • Figure 17: Asia Pacific Human Fibrinogen Concentrates Market Value (USD billion), by Application, 2024 & 2032
  • Figure 18: Asia Pacific Human Fibrinogen Concentrates Market Value Share (%), by Application, 2024
  • Figure 19: Asia Pacific Human Fibrinogen Concentrates Market Value (USD billion), by End-user, 2024 & 2032
  • Figure 20: Asia Pacific Human Fibrinogen Concentrates Market Value Share (%), by End-user, 2024
  • Figure 21: Asia Pacific Human Fibrinogen Concentrates Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
  • Figure 22: Asia Pacific Human Fibrinogen Concentrates Market Value Share (%), By Country/Sub-Region, 2024
  • Figure 23: Latin America Human Fibrinogen Concentrates Market Value (USD billion), by Application, 2024 & 2032
  • Figure 24: Latin America Human Fibrinogen Concentrates Market Value Share (%), by Application, 2024
  • Figure 25: Latin America Human Fibrinogen Concentrates Market Value (USD billion), by End-user, 2024 & 2032
  • Figure 26: Latin America Human Fibrinogen Concentrates Market Value Share (%), by End-user, 2024
  • Figure 27: Latin America Human Fibrinogen Concentrates Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
  • Figure 28: Latin America Human Fibrinogen Concentrates Market Value Share (%), By Country/Sub-Region, 2024
  • Figure 29: Middle East & Africa Human Fibrinogen Concentrates Market Value (USD billion), by Application, 2024 & 2032
  • Figure 30: Middle East & Africa Human Fibrinogen Concentrates Market Value Share (%), by Application, 2024
  • Figure 31: Middle East & Africa Human Fibrinogen Concentrates Market Value (USD billion), by End-user, 2024 & 2032
  • Figure 32: Middle East & Africa Human Fibrinogen Concentrates Market Value Share (%), by End-user, 2024
  • Figure 33: Middle East & Africa Human Fibrinogen Concentrates Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
  • Figure 34: Middle East & Africa Human Fibrinogen Concentrates Market Value Share (%), By Country/Sub-Region, 2024
  • Figure 35: Global Human Fibrinogen Concentrates Market Share (%), 2024